Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:00:38.577Z.
Calculation as of: 2026-10-06T19:00:38.577Z.
Quote observation: 2026-10-06T19:00:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6c02d81e284155bdcda1783dec911e9c0a395e203238f61c1cccf60d236910ce
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$8.91B
EBITDA Yield
0.70%
TTM Avg
0.48%
3Y Avg
4.02%
5Y Avg
4.02%
Market Cap
$8.78B
EBITDA Yield
N/A
TTM Avg
2.61%
3Y Avg
2.61%
5Y Avg
2.61%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | $9.03B | N/A | N/A | N/A | N/A |
| Bruker Corporation (BRKRP)vs › | $8.91B | 3.35% | 0.70% | 0.72% | 0.72% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.91B | 0.70% | 0.48% | 4.02% | 4.02% |
| Bruker Corporation (BRKR)vs › | $9.22B | 3.26% | 4.44% | 4.68% | 4.77% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.78B | N/A | 2.61% | 2.61% | 2.61% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.68B | N/A | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.38B | 6.35% | 4.06% | 2.63% | 1.89% |
| Vaxcyte, Inc. (PCVX)vs › | $9.47B | N/A | N/A | N/A | N/A |
| Krystal Biotech, Inc. (KRYS)vs › | $9.62B | 2.22% | 2.23% | 2.14% | 2.14% |
| Henry Schein, Inc. (HSIC)vs › | $9.64B | 8.17% | 8.49% | 8.43% | 8.63% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
